Miscellaneous
Frequency of Increase in Cardiac Troponin Levels After Peripheral Arterial Operations (Carotid Endarterectomy, Abdominal Aorta Procedure, Distal Bypass) and Their Effect on Medical Management

https://doi.org/10.1016/j.amjcard.2016.08.087Get rights and content

The utility of measuring cardiac troponins (cTn) in asymptomatic patients during the perioperative period has been controversial. In the present substudy of the Cardiac Remote Ischemic Preconditioning Prior to Elective Vascular Surgery Trial (NCT01558596), we hypothesized that surveillance of myocardial injury with cTnI in the perioperative period would lead to initiation or intensification of medical therapies for coronary artery disease. Increases in cTnI ≥0.01 μg/l in the perioperative period were considered clinically significant. Intensification of medical therapy was defined as initiation of aspirin or initiation or increases in the dose of angiotensin-converting-enzyme inhibitors or angiotensin-receptor blockers, statins, or β blockers and was left to the discretion of treating physicians. From June 2011 to April 2015, a total of 185 patients (mean age 68 ± 7 years, 100% men) were enrolled in the trial. A total of 28 patients (15%) had significant increases in cTnI after vascular surgery, and 38 (20.5%) had their medical therapies intensified in the perioperative period. Among patients with increases in cTnI, 11 (39%) had intensification of medical therapy versus 27 patients (17%) with no or smaller increases in cTnI (p = 0.02). Among those patients with ΔcTnI ≥0.01 μg/l, hospital readmissions at 3 to 6 months were 7.6% for the intensification group versus 25% for the no intensification group (p = 0.18). Mortality rate at 6 months was low in both groups (2.6% vs 0%, respectively, p = 0.13). In conclusion, among patients undergoing vascular surgery, perioperative increases in cTn were associated with initiation or intensification of medical therapies for coronary artery disease at the time of discharge.

Section snippets

Methods

The present study is a secondary analysis of the Cardiac Remote Ischemic Preconditioning Prior to Elective Vascular Surgery (CRIPES, NCT01558596), a prospective, single-center, randomized, sham-controlled phase 2 trial of remote ischemic preconditioning (RIPC) before elective vascular surgery. Details of the study protocol have been previously published.10 Briefly, CRIPES is testing whether a protocol of RIPC before vascular surgery reduces the proportion of subjects with a detectable increase

Results

From June 2011 to April 2015, a total of 185 patients were enrolled in the CRIPES trial. The mean age (±SD) of the population was 68 ± 7 years (100% male gender, 97% Caucasian). A total of 46 patients (24.8%) had cTnI elevations above the URL. Of those who had an increase in cTnI, the median (twenty-fifth to seventy-fifth percentile) ΔcTnI elevation in the perioperative period was 0.01 (0.003 to 0.12) μg/l. A total of 28 patients (15%) had ΔcTnI values ≥0.01 μg/l in the perioperative period,

Discussion

The main finding of our observational study is that a strategy of surveillance for myocardial injury in the perioperative period with cTnI may provide value by altering the clinician's decision to either initiate or intensify therapies that are known to improve long-term outcomes in patients with CAD. Even in a group of patients with peripheral arterial disease, in whom utilization rates of cardiac medications at baseline were high, the presence of dynamic serial cTnI concentration changes

References (19)

There are more references available in the full text version of this article.

Cited by (0)

See page 1933 for disclosure information.

View full text